Managing High-Risk Subgroups in Metastatic NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Melina Marmarelis, MD
Deepa Rangachari, MD
Optimizing cGVHD Treatment Decisions in the Second- and Third-Line Settings
Stephanie Gregory, CNP
Managing Immune-Related Adverse Events in Metastatic NSCLC
Paul Bunn, MD
Real-World Strategies for Complex cGVHD Treatment Decisions
Brian P. McDonough, MD, FAAFP
Doris M. Ponce, MD, MS
Emerging Therapeutic Strategies in Metastatic NSCLC
Urs Weber, MD
Interpreting Perioperative Trial Designs in Resectable NSCLC Research
Laura Alder, MD
Christine Bestvina, MD
Shared Decision-Making in Colorectal Cancer Screening
Gates B. Colbert, MD
Sarina Schrager, MD
Lashika Yogendran, MD
Turning Cold Tumors Hot with mRNA COVID-19 Vaccines
Hallie Blevins, PhD
Marlene Mimi Maeusli, PhD.
Navigating AKT Inhibitor-Associated Adverse Events in HR+/HER2- Advanced Breast Cancer
Alexandria May, PharmD, BCPS
Adam Brufsky, MD, PhD
Addressing Barriers to CAR T Referral in R/R LBCL
Steve Jackson, PharmD
Matthew J. Matasar, MD
Tycel Phillips, MD
Coordinating Care for mCSPC Patients Receiving Androgen Receptor Pathway Inhibitors
Daniel Geynisman, MD
Jonathan Henderson, MD
Optimizing Multidisciplinary Care in Perioperative NSCLC
David Tom Cooke, MD, FACS
Joshua Reuss, MD
Blood-Based Colorectal Cancer Screening: Where Do We Stand?
Peter Buch, MD, FACG, AGAF, FACP
Aasma Shaukat, MD, MPH
Choosing Between Neoadjuvant and Perioperative Strategies in NSCLC
Raghava Reddy Induru, MD
Managing AKT Inhibitor-Associated AEs in HR+/HER2- Advanced Breast Cancer
Neil M. Iyengar, MD
Sarah H. Donahue, MPH, NP
Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Bilal Siddiqui, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.